April 25, 2012
Japan Tobacco Inc. (JT) and Torii Pharmaceutical announced on April 23 that the hyperphosphatemia treatment JTT-751 (ferric citrate), which is under development in Japan, showed non-inferiority to the comparator drug in the GBA4-1 study, a PIII study conducted in Japan...read more